Drug intelligence / Profile preview

VNX-202

Development stage: Unknown
Lead developer: Vironexis Biotherapeutics
Modality: Gene Therapies
Administration: Intravenous

Overview

VNX-202 is an adeno-associated virus (AAV)-delivered gene therapy developed by Vironexis Biotherapeutics Inc. It is designed to encode a CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2). This gene therapy aims to redirect T-cells to target and eliminate HER2-positive cancer cells. It is currently undergoing a Phase 1/2 first-in-human clinical trial for patients with HER2-positive cancers.

Targets

CD3 (T-cell surface glycoprotein CD3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on VNX-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VNX-202.

Explore the full profile